US 12,404,507 B2
Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases
Michael Yoonsuk Choi, Boston, MA (US); and Byeong-Moo Kim, Wellesley, MA (US)
Assigned to THE GENERAL HOSPITAL CORPORATION
Filed by THE GENERAL HOSPITAL CORPORATION, Boston, MA (US)
Filed on Apr. 23, 2021, as Appl. No. 17/238,612.
Application 17/238,612 is a division of application No. 16/302,940, granted, now 11,015,196, previously published as PCT/US2017/033570, filed on May 19, 2017.
Claims priority of provisional application 62/339,431, filed on May 20, 2016.
Prior Publication US 2021/0238604 A1, Aug. 5, 2021
Int. Cl. C12N 15/113 (2010.01); A61K 35/407 (2015.01); A61P 1/16 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 35/407 (2013.01); A61P 1/16 (2018.01); C12N 2310/141 (2013.01); C12N 2330/50 (2013.01)] 16 Claims
 
1. A method for treating or delaying progression of a disease associated with activated hepatic stellate cells (HSCs) in a subject, the method comprising in vivo administering to a subject who has, is suspected of having, or at risk of having a disease associated with activated HSCs a first composition comprising miR-412, a miR-412 mimic or a nucleic acid sequence encoding miR-412,
wherein the disease associated with activated hepatic stellate cells (HSCs) is selected from the group consisting of: liver fibrosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis, biliary atresia, cirrhosis, nonalcoholic fatty liver disease (NAFLD), hepatic cancer, hepatic fibrosis, hepatic steatosis (fatty liver disease), Gilbert's syndrome, hemochromatosis, lysosomal acid lipase deficiency, primary biliary cholangitis, sarcoidosis, toxic hepatitis, tyrosinemia, viral hepatitis A, viral hepatitis B, viral hepatitis C, and Wilson disease.